Running an ANDA Litigation: A Practical Guide

Document type: Guide Practice area: Intellectual Property — Patents Jurisdiction: United States (federal) Last reviewed: 5 September 2026

ANDA litigation runs on two clocks that most patent lawyers never encounter: a 45-day window in which the brand must sue, and a 30-month stay against which the entire case is scheduled. Everything else — discovery, construction, expert work, trial — is fitted around those two numbers.

It also runs on a document most patent lawyers never see: the abbreviated new drug application itself, which is the accused product, the discovery target, and frequently the case.

This guide walks the work in the order it happens, from both sides.

PART ONE — THE GENERIC'S PRE-FILING WORK

Step 1: Build the patent landscape

Long before an application is filed, the generic team assembles the picture.

• Pull the Orange Book listing for the reference drug: every patent, its expiration, its use code, and its listing date.
• Pull the patent families, including unlisted patents, continuations, and foreign counterparts. Unlisted patents can still be asserted, just not through this framework.
• Map the regulatory exclusivities: new chemical entity, new clinical investigation, orphan, and pediatric. The entry date is the latest of everything, not the last patent to expire.
• Check patent term extension under 35 U.S.C. § 156 — which patent received it, and how the calculation ran.
• Identify the first-filing date: four years after NDA approval for a Paragraph IV filing against an NCE-exclusivity product, or immediately where no NCE exclusivity applies.
• Check who else is likely to file, from public statements, prior filings, and industry knowledge. Shared exclusivity changes the economics.

Step 2: Do the technical work

Formulation and process design. The single most valuable pre-filing investment is designing around the formulation patents — a different excipient, a different ratio, a different process — and documenting the design-around contemporaneously. That documentation becomes the non-infringement case.

Analytical characterization. For polymorph and crystalline form patents, characterize what the product actually contains, with the analytical methods the patent uses and with independent methods. This is the evidence.

Prior art search. A thorough search on every listed patent, focused on printed publications (usable at the PTAB) and on prior products and public uses (usable only in court).

Label analysis. For each method-of-use patent, determine whether a section viii carve-out is available and what would remain in the label after the carve-out. Read the use code carefully; if it is broader than the patent claims, consider the Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, 566 U.S. 399 (2012) counterclaim route.

Step 3: Choose the certifications

For each listed patent, decide:

• Paragraph III where the patent is strong and the expiry is acceptable. No litigation on that patent.
• Paragraph IV where you have a non-infringement or invalidity position. This starts a lawsuit.
• Section viii statement where the patent claims a method of use you can carve out.

These decisions are strategic, not mechanical. A generic that certifies Paragraph IV to five patents invites five patent cases; one that concedes the compound patent and challenges only the formulation patent runs a narrower, cheaper case aimed at the date that matters.

And they interact. A Paragraph IV to any patent makes you a potential first filer for exclusivity purposes. A conservative certification strategy may cost the exclusivity.

Step 4: Write the notice letter

The Paragraph IV notice must give a detailed statement of the factual and legal basis for the assertion of invalidity or non-infringement.

What to include:

• Identification of the ANDA and the drug product.
• For each patent, claim-by-claim analysis of non-infringement, with the ANDA formulation described at the level needed to show it.
• Invalidity contentions with the prior art, applied claim by claim.
• An offer of confidential access to the ANDA, with proposed terms.

Strategic considerations:

• This document locks in positions. Contentions that appear for the first time in litigation, absent from the notice letter, draw arguments that they are untimely or that the notice was inadequate.
• It is also a settlement document. A notice letter demonstrating a genuinely strong position sometimes produces a settlement before the complaint.
• Length is not strength. A focused letter with two solid grounds is more persuasive than 300 pages of everything.
• The offer of confidential access should be reasonable. Unreasonable terms delay the brand's analysis and invite a motion, and courts notice.

PART TWO — THE BRAND'S 45 DAYS

Step 5: Triage on day one

The notice letter arrives. The clock is 45 days, and the decision is whether to sue.

Day 1–3:

• Log the receipt date precisely. The 45 days and the 30-month stay both run from it.
• Distribute to the litigation team, regulatory affairs, and the business.
• Confirm which patents are certified to, and how.
• Identify whether a section viii carve-out is proposed and for which patent.
• Determine whether this is a first filer.

Day 3–10:

• Negotiate and execute the confidential access agreement. Do this immediately; every day of delay is a day of the 45 not spent on analysis.
• Obtain the ANDA.
• Assign the formulation, analytical, and regulatory review.

Day 10–35:

• Assess infringement of each certified patent against the ANDA as described.
• Assess the invalidity contentions.
• For any carved-out method patent, assess induced infringement: what remains in the proposed label, and what the applicant has said publicly.
• Identify which patents to assert.

Day 35–44:

• Draft and file the complaint.

Step 6: File within 45 days — essentially always

The arithmetic is not close. Filing produces a 30-month stay of FDA approval without any showing of likelihood of success or irreparable harm. For a product with meaningful revenue, thirty months of continued exclusivity dwarfs the litigation cost even if the brand ultimately loses every patent.

What to assert. All patents with a colorable position. A patent conceded now cannot be asserted later in this framework.

Where to file. Venue considerations are real and the districts differ in speed, familiarity, and scheduling practice. Consider where the applicant is incorporated and has facilities, and consider the district's ANDA docket.

The complaint is filed on incomplete information, and everyone knows it. Contentions get refined in discovery. Do not over-plead specifics you cannot support.

Sue every filer. Where multiple ANDAs are pending, coordinate the cases.

PART THREE — RUNNING THE CASE

Step 7: Schedule against the stay

The 30-month stay is the organizing fact of the case schedule.

A workable schedule, counting from the complaint:

What to raise at the Rule 16 conference:

• The stay expiration date, and a schedule that produces a decision before it.
• Whether claim construction will be combined with summary judgment.
• Coordination among multiple defendants: common invalidity issues briefed jointly, individual non-infringement issues separately.
• A protective order with a prosecution bar and a tiered confidentiality structure — the ANDA and the manufacturing process are among the most sensitive documents either party holds.
• Whether the court will bifurcate anything. Usually not; these cases are compact.

Step 8: Discovery, centered on the ANDA

What the brand seeks:

• The complete ANDA and every amendment, including the formulation, the manufacturing process, the analytical methods, the stability data, the dissolution profiles, and the proposed label.
• Batch records and samples for testing. Analytical testing of the applicant's actual product is frequently the decisive evidence on polymorph and formulation issues.
• Development documents: why the formulation was chosen, what alternatives were tried, whether a design-around was intentional.
• Communications with FDA, including deficiency letters and responses.
• Marketing, launch planning, and sales projections — relevant to induced infringement and to any at-risk launch analysis.
• Public statements: press releases, investor presentations, analyst call transcripts.

What the generic seeks:

• Prosecution files for every asserted patent, including foreign counterparts.
• Development and formulation records for the brand product, relevant to obviousness and to what the inventors actually did.
• Commercial success evidence and its basis, relevant to secondary considerations.
• Prior art in the brand's possession, including anything cited in foreign proceedings.
• Communications about the Orange Book listing decisions and the use codes.
• Any prior settlements or licenses with other ANDA filers, relevant to damages and to obviousness rebuttal.

Practical points:

• Get samples early. Testing takes weeks and the results shape everything.
• The offer of confidential access in the notice letter usually produces the ANDA before the complaint. Use it.
• Protective order sensitivity is high. Manufacturing processes and formulations are trade secrets on both sides, and the prosecution bar matters because the same lawyers may prosecute related applications.

Step 9: Claim construction

The Markman hearing is frequently dispositive in these cases, because the disputes are about ranges, measurement points, and compositional definitions.

The recurring dispute types:

• Range limitations — "about 5% to 15% by weight." What does "about" reach, and is the percentage measured before or after a processing step?
• Compositional terms — "a stabilizing agent," "an immediate-release layer." Does a component that serves two functions satisfy a limitation directed to one?
• Polymorph identification — how a crystalline form is defined and what analytical method controls.
• Method-of-use terms — what "treating" or "administering to a patient in need thereof" requires.

Strategy notes:

• The measurement question is often the case. Where a claim recites a property, whether it is measured on the finished product or on an intermediate can decide infringement entirely.
• Prosecution history matters heavily in this field, because the families are long, the arguments are extensive, and disclaimer arguments are common.
• Consider construction and summary judgment together. Where construction is dispositive, a combined submission saves months against the stay.

Step 10: Trial

Bench trial, typically three to eight days.

The brand's case: infringement, claim by claim, using the ANDA and the applicant's own test data; validity rebuttal including secondary considerations with real commercial data.

The generic's case: non-infringement based on what the product actually is; invalidity — obviousness of the formulation, polymorph, or dosing regimen, with obviousness-type double patenting frequently doing serious work; written description and enablement for genus and range claims.

Practical notes:

• Tutorials help. Most judges welcome a technology tutorial, and in a bench trial the judge is the audience for everything.
• Demonstratives on the formulation — the actual composition, side by side with the claim — do more than argument.
• Expert credibility is the case. These trials are expert-driven, and the expert who explains rather than advocates wins.
• Keep the record clean for appeal. The Federal Circuit reviews claim construction de novo and factual findings for clear error, and the findings are what you live with.

PART FOUR — THE SKINNY LABEL

Step 11: For the generic — carve out completely

A section viii carve-out is lawful. It is not a shield. Induced infringement liability turns on what the generic does after the carve-out.

The scrub list, all of which should be reviewed by counsel before launch:

• The proposed label: does anything remaining — dosing tables, pharmacology, clinical studies, warnings — relate specifically to the carved-out indication?
• Product catalogs and monographs.
• The company website and product pages.
• Press releases and investor presentations. "A generic version of [brand]" is the sentence that creates the exposure.
• Analyst call scripts and Q&A preparation.
• Sales training materials and detailing pieces.
• Payer and formulary submissions, including therapeutic equivalence statements.
• Third-party drug compendia entries the company can influence.
• Package inserts, cartons, and labeling artwork.

Document the review. A memorandum showing counsel reviewed the launch materials for carve-out compliance is worth a great deal when the brand's complaint quotes a stray sentence.

Train the commercial team. The people who write investor decks do not know what a section viii statement is. Tell them, in one paragraph, what they cannot say.

Step 12: For the brand — build the induced infringement record

Collect early and comprehensively. Most of the evidence is public and it disappears — websites change, presentations are replaced, press releases are archived.

• Capture the generic's website, product pages, and catalog with dated preservation.
• Collect every press release, investor presentation, and earnings call transcript.
• Obtain the proposed label and compare it line by line against the brand label; identify every retained element relevant to the carved-out use.
• Obtain sales and marketing materials in discovery.
• Consider physician and pharmacist evidence on how the product is actually used and substituted.

The theory to plead. Not that the carve-out is improper — it is lawful — but that the generic's label and communications encourage the patented use, with the specific language identified.

Be realistic. The Federal Circuit's decisions in this area have gone more than one way, and a case built on a single ambiguous sentence is a weak case. A case built on a label that retains dosing information relevant only to the patented indication is a strong one.

PART FIVE — THE PTAB DECISION

Step 13: Decide whether to file an IPR

In favor:

• Preponderance of the evidence rather than clear and convincing.
• Technically trained judges.
• A final written decision within twelve months of institution — sometimes faster than the district court.
• A second, independent shot at validity.

Against:

• 35 U.S.C. § 315(e) estoppel. A petitioner that reaches a final written decision cannot assert in the district court any ground it raised or reasonably could have raised. For a generic whose defense is largely printed-publication prior art, this can eliminate the invalidity case in the forum that decides infringement.
• Discretionary denial. Where the district court trial is scheduled before the Board's statutory deadline, institution may be denied. ANDA cases in fast districts are frequently in exactly that posture.
• It does not affect the 30-month stay. FDA approval is not conditioned on the Board.
• Non-infringement is unavailable at the Board, and eligibility is unavailable in an IPR under § 311.
• Prior public use and on-sale art cannot be raised in an IPR, only patents and printed publications.

The decision framework. File where the printed-publication art is strong, the district court trial date is late, and non-infringement is not the primary defense. Do not file where the case will be won on non-infringement and the estoppel would cost the backup invalidity defense.

Coordinate the claim positions. A narrow construction argued at the Board to avoid prior art can be quoted against you on infringement, and a broad construction argued in court to capture the brand product can be quoted at the Board. Assign one person to review every filing across both tracks.

PART SIX — SETTLEMENT, LAUNCH, AND ANTITRUST

Step 14: Settle on a date

The overwhelming majority of these cases settle, and the deal is an entry date.

What the parties negotiate:

• The entry date — the date the generic may launch, usually before patent expiry.
• Acceleration triggers — the generic enters earlier if another generic enters, if a court invalidates the patents, or on other defined events. Most-favored-entry provisions are standard.
• A license, typically royalty-free, effective on the entry date.
• Whether the brand may launch an authorized generic, and if so, when. This is frequently the most valuable term to the generic, because an authorized generic halves the value of 180-day exclusivity.
• Dismissal terms and the treatment of the certifications.

What makes it an antitrust event. After FTC v. Actavis, Inc., 570 U.S. 136 (2013), a settlement in which value flows from the brand to the generic is subject to rule-of-reason scrutiny, and the size of an unexplained payment is treated as a surrogate for the patent's weakness.

Structuring rules:

• Involve antitrust counsel in structuring, not in review. The analysis of whether consideration is justified must be contemporaneous.
• Document the litigation-cost justification with actual budget figures.
• Document independent value for any side deal — a supply agreement, a license to another product, a development collaboration. A side deal with no independent commercial rationale is the fact pattern the agencies pursue.
• A no-authorized-generic commitment is consideration. Treat it as such in the analysis.
• Report to the FTC and DOJ as the Medicare Modernization Act requires. Every settlement is reviewed.

Step 15: The at-risk launch decision

Where FDA has approved the ANDA and an appeal is pending, the generic may launch — and face damages if it loses.

Run the arithmetic explicitly:

The damages number is the point. Under § 271(e)(4), damages are available only where there has been commercial manufacture, use, or sale — which is exactly the at-risk launch. The brand's lost profits on a branded product can be many multiples of the generic's revenue, because the brand loses high-margin sales to a low-priced substitute.

Practical guidance: an at-risk launch is a board-level decision with a documented analysis, insurance review, and appellate counsel's written assessment. It is occasionally the right call. It is never a decision the deal team should make alone.

PART SEVEN — A WORKED CASE

Corvallis Therapeutics and Wexley Generics, on the facts described in the companion article.

Month 0. Wexley files, certifying Paragraph IV to the formulation patent, Paragraph III to the compound patent, and filing a section viii statement on the method-of-use patent.

Wexley's pre-filing work, done over eighteen months: it designed its formulation to use a different disintegrant at a ratio outside the claimed range, documented every formulation trial with the design-around rationale stated in the development report, and had outside counsel review the proposed label and the launch communications plan before the ANDA was submitted.

Month 0 + 20 days. Notice letter: 214 pages, two invalidity grounds and one non-infringement ground, offer of confidential access on standard terms.

Corvallis's 45 days. Confidential access executed on day 6. ANDA obtained on day 9. Formulation analysis complete on day 28. The team identifies that Wexley's excipient ratio is outside the literal range but arguably within it under a measurement theory, and that Wexley's proposed label retains a dosing table.

Day 44. Complaint filed in Delaware, asserting the formulation patent and the method-of-use patent on an induced infringement theory.

Month 3. Scheduling order: fact discovery closes month 14, Markman month 14, trial month 25.

Months 4–14. The decisive discovery: Corvallis obtains three commercial-scale batches and tests them. The measurement question — whether the excipient percentage is measured on the granulation or on the finished tablet — becomes the case. Wexley obtains Corvallis's formulation development records, which show the inventors tried the exact ratio Wexley uses and rejected it, which Wexley will use on obviousness and Corvallis will use on non-obviousness.

Month 14. Markman. The court construes the percentage as measured on the finished dosage form — Wexley's position.

Month 18. Wexley moves for summary judgment. Denied; a factual dispute about the test method.

Month 25. Four-day bench trial.

Month 29. Decision: no literal infringement, no infringement under the doctrine of equivalents (prosecution history estoppel from an amendment narrowing the range), and no induced infringement on the method patent. The court does not reach validity.

Month 31. Wexley launches with 180-day exclusivity. Corvallis launches an authorized generic on day one.

Total cost: Corvallis roughly $6.2 million; Wexley roughly $4.8 million. What Corvallis got for it: thirty months of exclusivity on a product generating about $40 million a month. The litigation paid for itself many times over on a case it lost.

What Wexley did right: the documented design-around, the label scrub, and choosing to challenge only the patent that mattered rather than certifying Paragraph IV to everything.

What Wexley did wrong: nothing material — but its exclusivity was worth roughly half what it projected, because the authorized generic was entirely foreseeable and was not modeled.

PART EIGHT — BUDGET, STAFFING, AND MISTAKES

Budget

Multiple defendants change the arithmetic. A brand facing five filers spends more in total but far less per case on the shared issues. Generics coordinating on invalidity split the largest expert cost.

Staffing

Brand side: a patent litigation partner who has tried ANDA cases; a formulation or analytical chemist as a technical advisor from day one; regulatory counsel who reads the ANDA as a regulatory document rather than as a technical one; antitrust counsel available before any settlement discussion; and a person who owns the 45-day calendar.

Generic side: the same, plus commercial counsel who owns the label and launch-materials scrub, and appellate counsel engaged before any at-risk launch decision.

Both sides: one person accountable for the stay date and the schedule against it. In a case organized around a clock, somebody must own the clock.

Mistakes that recur

Brand: missing or nearly missing the 45 days. Execute the confidential access agreement in week one.

Brand: asserting patents with no colorable position. It costs credibility, invites a § 285 motion, and rarely changes the entry date.

Brand: not preserving the generic's public statements early. They change and disappear.

Generic: certifying Paragraph IV to everything. It multiplies the litigation and rarely accelerates the date that matters.

Generic: an undocumented design-around. Contemporaneous development records showing the intentional design-around are the non-infringement case; reconstructing them later is much weaker.

Generic: an unscrubbed launch communication. One sentence in an investor deck is the induced infringement case.

Generic: filing an IPR without modeling the § 315(e) estoppel against the district court invalidity defense.

Either side: inconsistent claim positions across the district court and the Board. The most common self-inflicted wound.

Either side: settling without antitrust counsel in the room. Structure, not review.

Generic: modeling exclusivity without the authorized generic. It is foreseeable and it halves the number.

Either side: not calendaring the stay. Everything runs against it, and it is the one date the court will not move for convenience.

PART NINE — FREQUENTLY ASKED QUESTIONS

When exactly does the 30-month stay start? On the date the NDA holder or patent owner receives the Paragraph IV notice, not on the date of the complaint. Log the receipt date precisely.

Can we get a second stay by listing a new patent? No. One stay per ANDA. A newly listed patent requires a new certification and can be sued on, but without a second stay.

What if the generic will not give us the ANDA? The notice letter should contain an offer of confidential access. If the terms are unreasonable, negotiate quickly and, if necessary, move — but file the complaint within 45 days regardless.

Are these jury trials? No. Bench trials, because there are no damages in the ordinary case.

Can we get damages? Only where there has been commercial manufacture, use, or sale — an at-risk launch. See 35 U.S.C. § 271(e)(4).

Does the safe harbor protect commercial stockpiling? Section 271(e)(1) protects activity reasonably related to a regulatory submission, read broadly after Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005). Building commercial inventory has been litigated, and the analysis turns on whether the activity was regulatory or commercial preparation.

Is a skinny label safe? It is lawful and it is not a shield. Scrub the label and every downstream document, and have counsel document the review.

Should the generic file an IPR? Only after modeling the estoppel cost and the discretionary-denial risk against the district court trial date.

How do we value 180-day exclusivity? Assume an authorized generic launches on day one, because it usually does. Then model the forfeiture triggers.

Should we settle? Almost always, and the deal is a date. Bring antitrust counsel into the structuring conversation, not the review.

PART TEN — THE 505(b)(2) VARIANT

Companies developing a modified version of an approved drug — a new dosage form, a new strength, a new route, a fixed-dose combination — frequently enter this framework without realizing it.

What triggers it. A § 505(b)(2) application relies in part on FDA's findings for a previously approved drug, and the applicant must make the same certifications to the Orange Book patents listed against that reference product. A Paragraph IV certification produces the same notice letter, the same artificial act of infringement under § 271(e)(2), and the same 30-month stay.

What differs:

• No 180-day exclusivity. The generic incentive does not apply.
• The product is not substitutable. It is not therapeutically equivalent, so it competes on the merits rather than at the pharmacy counter — which changes the commercial model entirely.
• The applicant may earn its own exclusivities, including three-year exclusivity for the new clinical investigations it conducted, and its own patents on the modification.
• Both parties are often brand companies, which changes the settlement dynamics: neither wants a precedent, both have portfolios, and cross-licensing is more available than in a brand-generic case.

Decisions to make at the development stage, not at filing:

• Which reference product to cite. Different reference products carry different patent listings. Sometimes an older, less-patented reference is available.
• Which indications to seek. Seeking fewer indications may avoid method-of-use patents entirely.
• Whether the formulation can be designed outside the listed formulation patents, which is a development constraint and needs to reach the formulation scientists early.
• Whether to pursue a Paragraph IV or wait for expiry. A Paragraph III certification means approval at expiry with no litigation, which for a differentiated product with its own exclusivities is sometimes the better commercial answer.

The practical instruction. Bring patent counsel into the 505(b)(2) development program at the formulation stage. By the time the application is ready to file, the certification obligations are fixed and the litigation is determined by decisions made two years earlier.

PART TEN-B — MULTI-FILER COORDINATION

A brand facing five ANDA filers and a generic that is one of five run different cases from the single-filer version, and the coordination decisions are made in the first two months.

For the brand

Sue everyone. A filer not sued gets no stay, and a single unstayed approval collapses the market for all of them.

Seek consolidation for pretrial purposes. One claim construction, one set of validity expert reports, one Markman hearing. The infringement cases stay separate because the ANDAs differ.

Watch the differences between the ANDAs. Five applications with five formulations produce five non-infringement positions, and the strongest defendant sets the settlement price for the rest.

Sequence the settlements carefully. Settling with the first filer on a date, while litigating against subsequent filers, is common — but the first filer's 180-day exclusivity blocks the others, so the first settlement effectively sets the market entry date. Model the whole board before signing the first deal.

And model the forfeiture triggers. A first filer that forfeits exclusivity changes every subsequent filer's economics and may accelerate entry.

For the generic

Coordinate on invalidity, compete on non-infringement. A joint defense group sharing prior art, expert cost, and validity briefing saves each member a substantial share of the budget. Non-infringement is individual because each ANDA is different, and it should stay individual — a defendant whose formulation is clearly outside the claims should not have that position diluted.

Get the joint defense agreement right. Common interest privilege, what is shared and what is not, what happens on settlement, and whether a settling member's work product remains protected. Sign it before anything is exchanged.

Understand your position in the queue. A subsequent filer blocked by a first filer's exclusivity has a different objective — it may care more about the first filer's forfeiture triggers than about the merits.

Watch for the settlement that leaves you behind. If the first filer settles for an entry date and you are still litigating, your best outcome may now be that same date. Factor it into your own settlement posture early.

PART ELEVEN — WHERE TO GET HELP

A formulation or analytical chemist, from day one on both sides. These cases are decided by what the product actually is, measured how. A technical advisor who can read an ANDA and design a testing protocol is worth more than an additional associate, and finding the right one takes weeks.

Regulatory counsel who reads the ANDA as a regulatory document. Litigators read it for infringement; a regulatory lawyer sees the deficiency letters, the amendment history, and the FDA correspondence that tells you what the applicant struggled with.

Antitrust counsel before any settlement conversation. Not to review a term sheet — to structure it. The justification analysis must be contemporaneous, and every settlement is reported to the agencies.

Appellate counsel before an at-risk launch. The written assessment of reversal probability is the document a board needs, and it should be prepared by someone who has argued at the Federal Circuit rather than by the trial team.

Local counsel in Delaware or New Jersey. These districts have deep ANDA practice, published scheduling preferences, and judges with settled views on the recurring issues. That knowledge is not in the reported decisions.

Commercial counsel for the label and launch scrub, on the generic side. The people writing the investor deck do not know what a section viii statement is, and one sentence is the induced infringement case.

And your own regulatory affairs group. The certification decisions, the carve-out feasibility, and the exclusivity calculations are regulatory judgments with litigation consequences. The most expensive mistakes in this practice are made before anyone talks to a litigator.

PART TWELVE — THE ONE-PAGE VERSION

The generic, before filing: map every listed patent and every regulatory exclusivity, because the entry date is the latest of all of them. Design around the formulation patents and document it contemporaneously. Choose certifications strategically rather than reflexively. Write a focused notice letter with a reasonable offer of confidential access.

The brand, on receiving notice: log the receipt date, execute confidential access in week one, analyze the ANDA, and file within 45 days. The stay is worth more than the merits.

Both sides, in the case: schedule against the stay, center discovery on the ANDA, test the actual product, and treat claim construction — especially measurement and range questions — as potentially dispositive.

The generic, on the skinny label: carve out completely, scrub every downstream document, and have counsel document the review. The exposure is one sentence in an investor deck.

The brand, on induced infringement: preserve the generic's public statements early, and build the case from the label and the defendant's own materials.

The generic, on the PTAB: model the § 315(e) estoppel and the discretionary-denial risk before filing. Do not trade your invalidity defense for a forum that cannot decide infringement.

Both sides, on settlement: the deal is a date, plus acceleration triggers, plus the authorized-generic term. Structure it with antitrust counsel in the room, document the justifications contemporaneously, and expect the agencies to read it.

And the framing to keep in mind throughout: this is not a case about money. It is a case about a date, and every decision either side makes should be measured against how it moves that date.

Related documents

• Hatch-Waxman Litigation: The Orange Book, Paragraph IV Certifications, and the 30-Month Stay
• Paragraph IV and ANDA Litigation Checklist: A Practical Checklist
• Hatch-Waxman Toolkit: Notice Letters, Complaints, and Settlement Considerations
• Biologics and the BPCIA: The Patent Dance, Biosimilar Approval, and Exclusivity
• Preparing for a Markman Hearing: A Practical Guide
• Patent Post-Grant Proceedings: IPR, PGR, and Reexamination at the PTAB
• Proving and Attacking Patent Damages: A Practical Guide

This guide is general information, not legal advice, and does not create an attorney-client relationship.